Aripiprazole for Tourette's syndrome: A systematic review and meta-analysis

Abstract

Objective To review the efficacy and safety of aripiprazole (ARI) for Tourette's syndrome (TS). Methods This review included randomized controlled trials (RCTs) of children and adolescents (6-18 years) with TS comparing ARI monotherapy with another monotherapies in relation to clinical improvement and adverse events. Results Six RCTs with a total of 528 subjects (ARI treatment group: n = 253; control group: n = 275) met the inclusion criteria. These included two RCTs (n = 255) that compared ARI monotherapy with tiapride (TIA). Tic symptoms control assessed by Yale Global Tic Severity Scale (Standard Mean Difference (SMD) = -0.38 (Confidence Interval (CI) = -1.32 to 0.56); I2 = 90%, P = 0.42)..